Iskra Pusic

8.2k total citations · 2 hit papers
77 papers, 2.5k citations indexed

About

Iskra Pusic is a scholar working on Hematology, Public Health, Environmental and Occupational Health and Genetics. According to data from OpenAlex, Iskra Pusic has authored 77 papers receiving a total of 2.5k indexed citations (citations by other indexed papers that have themselves been cited), including 66 papers in Hematology, 23 papers in Public Health, Environmental and Occupational Health and 16 papers in Genetics. Recurrent topics in Iskra Pusic's work include Hematopoietic Stem Cell Transplantation (48 papers), Acute Myeloid Leukemia Research (23 papers) and Acute Lymphoblastic Leukemia research (23 papers). Iskra Pusic is often cited by papers focused on Hematopoietic Stem Cell Transplantation (48 papers), Acute Myeloid Leukemia Research (23 papers) and Acute Lymphoblastic Leukemia research (23 papers). Iskra Pusic collaborates with scholars based in United States, United Kingdom and Canada. Iskra Pusic's co-authors include John F. DiPersio, Mary E.D. Flowers, Madan Jagasia, Peter Westervelt, Geoffrey L. Uy, Ravi Vij, Stephanie J. Lee, Keith Stockerl‐Goldstein, Joseph Pidala and Amanda F. Cashen and has published in prestigious journals such as Nature, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Iskra Pusic

72 papers receiving 2.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

SARS-CoV-2 infection induces long-lived bone marrow plasma cells in humans

2021 306 citations Jackson S. Turner, Wooseob Kim et al. Nature profile →
Measuring Therapeutic Response in Chronic Graft-versus-Host Disease. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. The 2014 Response Criteria Working Group Report

2015 280 citations Stephanie J. Lee, Yoshihiro Inamoto et al. Biology of Blood and Marrow Transplantation profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Iskra Pusic United States	22	1.7k	655	452	441	357	77	2.5k
Prakash Satwani United States	28	1.0k 0.6×	474 0.7×	550 1.2×	453 1.0×	325 0.9×	138	2.1k
Claire Galambrun France	29	1.3k 0.7×	494 0.8×	395 0.9×	483 1.1×	583 1.6×	79	2.5k
Julián Sevilla Spain	26	1.2k 0.7×	640 1.0×	485 1.1×	295 0.7×	162 0.5×	130	2.3k
Gérard Socié France	18	1.9k 1.1×	514 0.8×	431 1.0×	882 2.0×	499 1.4×	39	2.8k
Fen Huang China	26	1.2k 0.7×	431 0.7×	566 1.3×	551 1.2×	408 1.1×	155	2.2k
Minoo Battiwalla United States	28	1.2k 0.7×	727 1.1×	680 1.5×	459 1.0×	307 0.9×	142	2.6k
Shelly L. Carter United States	20	1.6k 1.0×	644 1.0×	639 1.4×	441 1.0×	313 0.9×	30	2.3k
Voravit Ratanatharathorn United States	29	2.0k 1.2×	1.1k 1.7×	857 1.9×	369 0.8×	432 1.2×	140	3.6k
Kazuko Kudo Japan	30	1.3k 0.8×	406 0.6×	631 1.4×	199 0.5×	452 1.3×	102	2.4k
Marta González‐Vicent Spain	26	1.0k 0.6×	504 0.8×	633 1.4×	286 0.6×	262 0.7×	133	2.0k

Countries citing papers authored by Iskra Pusic

Since Specialization

Citations

This map shows the geographic impact of Iskra Pusic's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Iskra Pusic with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Iskra Pusic more than expected).

Fields of papers citing papers by Iskra Pusic

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Iskra Pusic. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Iskra Pusic. The network helps show where Iskra Pusic may publish in the future.

Co-authorship network of co-authors of Iskra Pusic

This figure shows the co-authorship network connecting the top 25 collaborators of Iskra Pusic. A scholar is included among the top collaborators of Iskra Pusic based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Iskra Pusic. Iskra Pusic is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Bloom, Michelle, Jose Alvarez‐Cardona, Sarju Ganatra, et al.. (2024). How to utilize current guidelines to manage patients with cancer at high risk for heart failure. Cardio-Oncology. 10(1). 63–63.

Friedman, Danielle Novetsky, Chaya S. Moskowitz, Kimberly L. Turner, et al.. (2023). Clonal hematopoiesis in survivors of childhood cancer. Blood Advances. 7(15). 4102–4106. 13 indexed citations

Choi, Jaebok, Matthew Cooper, Mark A. Fiala, et al.. (2023). Phase I-II Trial of Early Azacitidine after Matched Unrelated Donor Hematopoietic Cell Transplantation. Transplantation and Cellular Therapy. 29(11). 699.e1–699.e9. 2 indexed citations

Friedman, Danielle Novetsky, Chaya S. Moskowitz, Kimberly L. Turner, et al.. (2023). Clonal hematopoiesis in survivors of childhood cancer.. Journal of Clinical Oncology. 41(16_suppl). 10014–10014. 1 indexed citations

Abboud, Ramzi, Feng Gao, Michael P. Rettig, et al.. (2022). A Single-Arm, Open-Label, Pilot Study of the JAK1 Selective Inhibitor Itacitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome in T-Cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation. Transplantation and Cellular Therapy. 28(3). S298–S299. 1 indexed citations

Pusic, Iskra, Tanner M. Johanns, Stefanie Sarantopoulos, et al.. (2021). Use of Belimumab for Prophylaxis of Chronic Graft-Versus-Host Disease. Blood. 138(Supplement 1). 3904–3904. 1 indexed citations

Turner, Jackson S., Wooseob Kim, Elizaveta Kalaidina, et al.. (2021). SARS-CoV-2 infection induces long-lived bone marrow plasma cells in humans. Nature. 595(7867). 421–425. 306 indexed citations breakdown →

Rettig, Michael P., Amanda F. Cashen, John F. DiPersio, et al.. (2021). Combination of dociparstat sodium (DSTAT), a CXCL12/CXCR4 inhibitor, with azacitidine for the treatment of hypomethylating agent refractory AML and MDS. Leukemia Research. 110. 106713–106713. 14 indexed citations

Wong, Winghing, Sima Bhatt, Kathryn Trinkaus, et al.. (2020). Engraftment of rare, pathogenic donor hematopoietic mutations in unrelated hematopoietic stem cell transplantation. Science Translational Medicine. 12(526). 36 indexed citations

10.

Waller, Edmund K., David B. Miklos, Corey Cutler, et al.. (2019). Ibrutinib for Chronic Graft-versus-Host Disease After Failure of Prior Therapy: 1-Year Update of a Phase 1b/2 Study. Biology of Blood and Marrow Transplantation. 25(10). 2002–2007. 66 indexed citations

11.

Ali, Alaa M., Feng Gao, Geoffrey L. Uy, et al.. (2017). Patterns of infectious complications in acute myeloid leukemia and myelodysplastic syndromes patients treated with 10‐day decitabine regimen. Cancer Medicine. 6(12). 2814–2821. 21 indexed citations

12.

Cashen, Amanda F., John F. DiPersio, Meagan A. Jacoby, et al.. (2017). A Pilot Study of CX-01 with Azacitidine for Treatment of Hypomethylating Agent-Refractory AML and MDS. Blood. 130. 5067–5067. 3 indexed citations

13.

Yu, Jeffrey, Barry E. Storer, Kushi Kushekhar, et al.. (2016). Biomarker Panel for Chronic Graft-Versus-Host Disease. Journal of Clinical Oncology. 34(22). 2583–2590. 89 indexed citations

14.

Rashidi, Armin, John F. DiPersio, Peter Westervelt, et al.. (2016). Peritransplant Serum Albumin Decline Predicts Subsequent Severe Acute Graft-versus-Host Disease after Mucotoxic Myeloablative Conditioning. Biology of Blood and Marrow Transplantation. 22(6). 1137–1141. 8 indexed citations

15.

Duraković, Nadira, Ivan Krečak, Zinaida Perić, et al.. (2016). Glycoprotein YKL-40: a novel biomarker of chronic graft-vs-host disease activity and severity?. Croatian Medical Journal. 57(3). 239–246. 2 indexed citations

16.

Cheng, Guang‐Shing, Barry E. Storer, Jason W. Chien, et al.. (2016). Lung Function Trajectory in Bronchiolitis Obliterans Syndrome after Allogeneic Hematopoietic Cell Transplant. Annals of the American Thoracic Society. 13(11). 1932–1939. 49 indexed citations

17.

Miklos, David B., Corey Cutler, Mukta Arora, et al.. (2016). Multicenter Open-Label Phase 2 Study of Ibrutinib in Chronic Graft Versus Host Disease (cGVHD) after Failure of Corticosteroids. Blood. 128(22). LBA–3. 14 indexed citations

18.

Pusic, Iskra, Jaebok Choi, Mark A. Fiala, et al.. (2015). Maintenance Therapy with Decitabine after Allogeneic Stem Cell Transplantation for Acute Myelogenous Leukemia and Myelodysplastic Syndrome. Biology of Blood and Marrow Transplantation. 21(10). 1761–1769. 123 indexed citations

19.

Arora, Mukta, Corey Cutler, Madan Jagasia, et al.. (2015). Late Acute and Chronic Graft-versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation. 22(3). 449–455. 96 indexed citations

20.

Pusic, Iskra & John F. DiPersio. (2010). Update on clinical experience with AMD3100, an SDF-1/CXCL12–CXCR4 inhibitor, in mobilization of hematopoietic stem and progenitor cells. Current Opinion in Hematology. 17(4). 319–326. 112 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact